A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography

Bracco

Status and phase: Completed; Phase 4

Conditions: CIN

Treatments: Drug: Iopamidol 370 mgI/mL

Study type: Interventional

Funder types: Industry

Identifiers

NCT00289029

IOP104

Details and patient eligibility

About

The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with moderate to severe renal insufficiency undergoing cardiac angiography. Serum creatinine will be measured before and up to 48-72 hours after the administration of the contrast agent to evaluate renal function.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Referred for cardiac angiography; with a documented predose eGFR of greater than or equal to 20 and less than 60 mL/min/1.73m2

Exclusion criteria

• Unstable renal function; concurrent administration of nephrotoxic drugs, undergoing dialysis